ASCO 2021: HER2CLIMB Update Shows Benefits of Adding Tucatinib to Trastuzumab and Capecitabine Are Maintained in Metastatic Breast Cancer
With an additional 15.6 months of follow-up, overall and progression-free survival improvements remained
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.